Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 485,847 shares of the biopharmaceutical company's stock after selling 14,427 shares during the period. Regeneron Pharmaceuticals accounts for about 1.3% of BNP PARIBAS ASSET MANAGEMENT Holding S.A.'s holdings, making the stock its 9th biggest holding. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.44% of Regeneron Pharmaceuticals worth $510,741,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of REGN. SteelPeak Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock worth $1,148,000 after buying an additional 692 shares during the period. Atria Investments Inc boosted its stake in Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company's stock worth $8,317,000 after buying an additional 941 shares during the period. Mizuho Securities USA LLC boosted its stake in Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock worth $62,382,000 after buying an additional 51,162 shares during the period. Tri Locum Partners LP boosted its stake in shares of Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock valued at $18,410,000 after purchasing an additional 8,949 shares during the period. Finally, Tidal Investments LLC boosted its stake in shares of Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company's stock valued at $4,774,000 after purchasing an additional 711 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 7.48% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on REGN. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price objective for the company. Oppenheimer lowered their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a report on Thursday, October 24th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Stock Up 1.3 %

NASDAQ REGN traded up $9.71 on Thursday, reaching $753.06. The company had a trading volume of 316,779 shares, compared to its average volume of 534,249. The firm has a market capitalization of $82.75 billion, a PE ratio of 18.40, a P/E/G ratio of 2.81 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The firm has a 50-day moving average of $961.76 and a 200-day moving average of $1,030.14. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.